Organisation paid for research Program year 2025 Source: CMS Open Payments

Stacy Smith MD Apc

Neither a doctor nor a teaching hospital

Research payments

$2,356,777

87 payments

Through program year 2025, Stacy Smith MD Apc is reported as receiving $2,356,777 in research payments, across 87 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$112,762	7
2024	Research	$37,021	5
2023	Research	$99,330	6
2022	Research	$128,663	8
2021	Research	$419,172	33
2020	Research	$541,281	15
2019	Research	$1,018,548	13

Breakdown

Who paid Research payments · program years 2019–2025

Eli Lilly and Company $2,356,777 87 payments

Studies the money was for Research payments · program years 2019–2025

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Or Very Severe Alopecia Areata $854,849 13 payments
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-To-Severe Plaque Psoriasis $341,883 3 payments
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis $268,778 11 payments
Assessment of Safety, Tolerability, and Efficacy of Ly3303560 in Early Symptomatic Alzheimer's Disease $188,260 4 payments
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis $163,649 4 payments
A Multicenter, Long-Term Extension to Evaluate the Long-Term Safety and Maintenance of Treatment Effect of Ly3074828 in Patients With Moderate-To-Severe Plaque Psoriasis Oasis-3 $107,865 7 payments
A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis $99,806 3 payments
Efficacy and Safety of Ixekizumab Or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderate-To-Severe Plaque Psoriasis and Obesity Or Overweight: A Phase 3B, Randomized, Multicenter, Open-Label Study (Together-Pso) $92,683 3 payments
A Multicenter Randomized Double-Blind Placebo-Controlled Operationally Seamless Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Or Very Severe Alopecia Areata $80,149 2 payments
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Ly3471851 in Patients With Atopic Dermatitis $51,592 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.